MHRA consulting for ‘no deal’ Brexit
This article is powered by OTC Bulletin & The Rose Sheet
Executive Summary
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is consulting on proposed changes to the way it would regulate medicinal products in the country in the event of a ‘no deal’ UK exit from the European Union (EU) on 29 March 2019.
You may also be interested in...
Supply Of 'Important' OTCs From EU Prioritized In Event Of No Deal Brexit
In preparation for a possible no deal Brexit, the UK government is prioritizing supply from the EU those OTC medicines deemed "important for the management of specific health conditions." The Department of Health and Social Care says it is continuing to work closely with OTC manufacturers and suppliers to prepare for Brexit.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.